Pour rechercher une publication scientifique, insérez vos mots-clés en anglais.

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.


Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results.

Rodriguez CA Lodi S Horsburgh CR Mitnick CD Bastard M Huerga H Khan U Rich M Seung KJ Atwood S Manzur-Ul-Alam M Melikyan N Mpinda S Myint Z Naidoo Y Petrosyan O Salahuddin N Sarfaraz S Vilbrun SC Yae K Achar J Ahmed S Algozhina E Beauchamp J de Guadelupe Perea Moreno S Gulanbaeva M Gergedava M Indah Sari CY Hewison C Khan P Franke MF
PLOS global public health 2023 ; 3(4); . doi: 10.1371/journal.pgph.0000818. Epub 2023 04 28
Campbell JR Chan ED Anderson LF Bonnet M Brode SK Cegielski JP Guglielmetti L Singla R Fox GJ Skrahina A Rodrigues D Kuksa L Viiklepp P Menzies D
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023 Apr 01; 27(4); . doi: 10.5588/ijtld.22.0678. Epub 2023 04 10

Mortality and Cause of Death in Children With Presumptive Disseminated Tuberculosis.


BACKGROUND AND OBJECTIVES: Children experience high tuberculosis (TB)-related mortality but causes of death among those with presumptive TB are poorly documented.

Bonnet M Nordholm AC Ssekyanzi B Byamukama O Orikiriza P Tusabe T Nyehangane D Taremwa IM Turyashemererwa E Wobudeya E Mwanga-Amumpaire J Marais BJ Nampijja D
Pediatrics 2023 Apr 01; 151(4); . doi: 10.1542/peds.2022-057912. Epub 2023 04 04

A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol.


BACKGROUND: Lassa fever (LF), a haemorrhagic illness caused by the Lassa fever virus (LASV), is endemic in West Africa and causes 5000 fatalities every year.

Penfold S Adegnika AA Asogun D Ayodeji O Azuogu BN Fischer WA Garry RF Grant DS Happi C N'Faly M Olayinka A Samuels R Sibley J Wohl DA Accrombessi M Adetifa I Annibaldis G Camacho A Dan-Nwafor C Deha ARE DeMarco J Duraffour S Goba A Grais R Günther S Honvou ÉJJP Ihekweazu C Jacobsen C Kanneh L Momoh M Ndiaye A Nsaibirni R Okogbenin S Ochu C Ogbaini E Logbo ÉPMA Sandi JD Schieffelin JS Verstraeten T Vielle NJ Yadouleton A Yovo EK
PloS one 2023 ; 18(3); . doi: 10.1371/journal.pone.0283643. Epub 2023 03 30

It takes more than a machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health center in rural western Uganda.


Barriers continue to limit access to viral load (VL) monitoring across sub-Saharan Africa adversely impacting control of the HIV epidemic.

Boyce RM Ndizeye R Ngelese H Baguma E Shem B Rubinstein RJ Rockwell E Lotspeich SC Shook-Sa BE Ntaro M Nyehangane D Wohl DA Siedner MJ Mulogo EM
PLOS global public health 2023 ; 3(3); . doi: 10.1371/journal.pgph.0001678. Epub 2023 03 27

Assessment of the proportion of households with burn victims, associated risk factors and knowledge of burn injury prevention strategies in South Western Uganda. A population based cross sectional survey.


BACKGROUND: Burn injuries are a major cause of morbidity and mortality within Low- and Middle-income countries (LMICs). Most of these burn injuries occur at home with children most at risk.

Martin T Nanjebe D Atwine D
Burns : journal of the International Society for Burn Injuries 2023 Mar 24; . doi: 10.1016/j.burns.2023.03.016. Epub 2023 03 24
Adults Burn prevention Children Electricity protective Household burns Uganda

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver-child dyads' perspective.


BACKGROUND: Worldwide, 1.7 million children younger than 15 years were living with HIV in 2021. Only 52% of them had access to antiretrovirals (ARVs). Lack of age-appropriate ARV formulations (i.e.

Rotsaert A Ogara C Mwanga-Amumpaire J Kekitiinwa AR Musiime V Najjingo E Kisitu GP Nazzinda R Nambi E Lee J Diallo M Kyomuhendo F Waweru M Andrieux-Meyer I Nöstlinger C
Therapeutic advances in infectious disease 2023 ; 10; . doi: 10.1177/20499361231159993. Epub 2023 03 21
HIV acceptability antiretroviral therapy fixed-dose combination paediatric ARV

Protection, health seeking, or a laissez-passer: Participants' decision-making in an EVD vaccine trial in the eastern Democratic Republic of the Congo.


During the 10th Ebola virus disease (EVD) epidemic in the eastern Democratic Republic of the Congo (DRC) (2018-2020), two experimental EVD vaccines were deployed in North Kivu.

James M Kasereka JG Kasiwa B Kavunga-Membo H Kambale K Grais R Muyembe-Tamfum JJ Bausch DG Watson-Jones D Lees S
Social science & medicine (1982) 2023 Mar 15; 323; . doi: 10.1016/j.socscimed.2023.115833. Epub 2023 03 15
Clinical trials DRC Ebola Epidemics Vaccine